DoxyPEP Helps Reduce Sexually Transmitted Infections in California
DoxyPEP Shows Promise in Reducing STIs in San Francisco
San Francisco, CA – A new study published in JAMA Internal Medicine suggests that a novel approach to STI prevention, known as doxyPEP, is making a real-world impact in San Francisco. The strategy involves taking a single dose of the antibiotic doxycycline within 72 hours of sex to prevent bacterial STIs.
The study, conducted by the San Francisco Department of Public Health, analyzed data from three major sexual health clinics in the city. Researchers compared STI rates before and after San Francisco became the first city in the U.S. to recommend doxyPEP in October 2022.
“Our findings show a significant decline in chlamydia and early syphilis cases after the implementation of doxyPEP,” said Madeline Sankaran, MPH, epidemiologist with the San Francisco Department of Public Health and lead author of the study.”This is encouraging news and suggests that doxyPEP could be a valuable tool in our fight against STIs.”
The study found no significant reduction in gonorrhea cases, echoing results from previous clinical trials.
San Francisco’s doxyPEP program goes beyond the Centers for Disease Control and Prevention’s national guidelines, offering the preventative measure to a broader range of individuals, including transgender men and nonbinary people.
“We’re committed to exploring innovative approaches to sexual health,” said Dr. [Insert Name], Director of the San Francisco Department of Public Health.”the early success of doxyPEP in our city highlights the importance of proactive STI prevention strategies.”
While the study offers promising results, researchers emphasize the need for continued monitoring and further research to understand the long-term impact of doxyPEP and address concerns about potential antibiotic resistance.
The San francisco study adds to a growing body of evidence supporting the potential of doxyPEP as a valuable tool in the fight against STIs. As cities across the country grapple with rising STI rates, doxyPEP may offer a new avenue for prevention and public health intervention.
DoxyPEP Shows Promise in Curbing STIs Among high-Risk Groups in San Francisco
San Francisco, CA – A new wave of STI prevention is showing promising results in San Francisco, with studies indicating a significant decline in chlamydia and syphilis cases among men who have sex with men (MSM) and transgender women following the implementation of doxyPEP.
DoxyPEP, short for doxycycline post-exposure prophylaxis, involves taking a single dose of the antibiotic doxycycline after potential exposure to sexually transmitted infections (STIs). San Francisco became the first major U.S. city to recommend doxyPEP for MSM and transgender women at high risk for STIs in late 2022.
San Francisco Department of Public Health study
A study published in the journal Clinical Infectious Diseases examined the impact of doxyPEP on STI rates among MSM and transgender women in San Francisco. Researchers analyzed data from three sexual health clinics that began offering doxyPEP by the end of 2023.
The study found a dramatic decrease in chlamydia and syphilis cases after the implementation of doxyPEP. chlamydia cases fell by 50% compared to predicted levels, while early syphilis decreased by 51%.
“This study suggests that San Francisco’s doxyPEP guideline release was associated with decreases in reported cases of chlamydia and early syphilis, but not gonorrhea, among [men who have sex with men] and transgender women in San Francisco,” the study authors concluded. “Supporting doxyPEP implementation for [men who have sex with men] and transgender women at risk for STIs could have a significant impact on the nationwide STI epidemic.”
While the study showed a small increase in gonorrhea cases, researchers noted that further analysis is needed to determine if these declines will be sustained and to monitor for potential side effects, such as antibiotic resistance.
Kaiser Permanente Northern california study
A separate study published in JAMA Internal Medicine also found promising results for doxyPEP. Researchers at Kaiser Permanente Northern California analyzed data from over 11,000 people receiving HIV pre-exposure prophylaxis (PrEP) between November 2020 and December 2023.
Nearly one in five PrEP recipients also received doxyPEP. Among those who did, quarterly STI rates dropped significantly after starting prophylactic doxycycline. Chlamydia fell by 79%, syphilis declined by 80%, and gonorrhea decreased by 12%.
“Our patients have enthusiastically embraced this proactive approach to reduce their STI risk,” said study co-author Dr. Jonathan Volk of kaiser Permanente San Francisco. “After doxyPEP became available for our PrEP patients,we have seen a dramatic decline in positive STI tests and less need for treatment after STI exposures.”
A New Era of STI Prevention?
These studies offer encouraging evidence that doxyPEP can be an effective tool in the fight against STIs, notably among high-risk populations.While more research is needed to fully understand the long-term impact and potential risks of doxyPEP, these findings suggest a promising new avenue for STI prevention.
DoxyPEP Shows Promise in Reducing Chlamydia and Syphilis, But Gonorrhea Remains a Challenge
New research suggests that doxyPEP, a preventative strategy using the antibiotic doxycycline, is effective in lowering rates of chlamydia and syphilis, but its impact on gonorrhea is less clear.
The studies, published in JAMA Internal Medicine, examined the effectiveness of doxyPEP among individuals already using HIV pre-exposure prophylaxis (PrEP).
“We found significant reductions in chlamydia and syphilis incidence and modest declines in urethral and rectal gonorrhea incidence among individuals using HIV PrEP,” the study authors concluded.
Dr. Julia Volk, lead author of one of the studies, emphasized the need for continued STI testing for those on doxyPEP. “These modest reductions in gonorrhea rates reinforce the importance of regular STI testing for patients on doxyPEP and the need for novel prevention strategies for gonorrhea prevention, like vaccines that are currently in growth,” she said.
Mixed Results Highlight Need for further Research
While the findings are encouraging for chlamydia and syphilis prevention, the less pronounced effect on gonorrhea raises concerns. Experts caution that the prevalence of drug-resistant gonorrhea might potentially be a contributing factor.
In an accompanying commentary, Dr. Jeanne Marrazzo, director of the National Institute of Allergy and Infectious Diseases (NIAID), and Dr. Jodie Dionne of the University of Alabama at Birmingham, stressed the importance of monitoring antimicrobial resistance in doxyPEP users.
“These reports are part of the crucial scientific process of translating clinical research to implementation at scale,” Dr. Marrazzo said in a NIAID news release. “doxypep is proving to be an important intervention in our effort to decrease STI incidence while we continue to invest in research to develop safe and effective preventive vaccines and next-generation antibiotics.”
Despite the mixed results, doxyPEP remains a promising tool in the fight against STIs. Ongoing research and monitoring will be crucial to maximizing its effectiveness and addressing the challenges posed by drug-resistant infections.
DoxyPEP Shows Promise in Reducing STIs: A Q&A with san Francisco Health Officials
San Francisco has been at the forefront of innovative approaches to STI prevention,and the recent implementation of doxyPEP has garnered significant attention.
We spoke with Dr. [Insert Name], Director of the san Francisco Department of Public Health, to discuss the encouraging results of this novel approach.
Q&A with Dr. [Insert Name], Director, San Francisco Department of Public Health
What is doxyPEP and how does it work?
DoxyPEP, short for doxycycline post-exposure prophylaxis, involves taking a single dose of the antibiotic doxycycline within 72 hours of possible exposure to sexually transmitted infections. It helps prevent bacterial STIs like chlamydia, syphilis, and gonorrhea.
What prompted san Francisco to implement doxyPEP?
San Francisco has long been committed to proactive and innovative approaches to sexual health. We are seeing rising rates of STIs nationwide, and traditional prevention methods haven’t fully addressed this issue.
DoxyPEP presented a promising chance to potentially significantly reduce new infections, particularly among high-risk populations.
The recent studies from both the San Francisco Department of Public Health and Kaiser Permanente Northern California show encouraging results. Can you highlight the key findings?
The studies demonstrated a considerable decline in chlamydia and syphilis cases following the implementation of doxyPEP. This is incredibly encouraging and supports the potential effectiveness of this approach. While we saw a slight increase in gonorrhea cases,further analysis is required to understand this trend.
What are the next steps for San Francisco regarding doxyPEP?
We will continue to closely monitor the impact of doxyPEP, collecting data on STI rates, potential side effects, and adherence to the program. We are also exploring ways to expand access to doxyPEP and reach more individuals who could benefit from it.
Looking Ahead: A Potential Game-Changer?
The initial results of doxyPEP implementation in San Francisco are promising and suggest a potential turning point in STI prevention. While further research is necessary, this approach could significantly impact STI rates nationwide if proven to be safe and effective in the long term.
San Francisco’s commitment to innovative public health strategies serves as a model for other cities facing the challenge of rising STI rates.